Cognition Therapeutics Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 25

Employees

  • Stock Symbol
  • CGTX

Stock Symbol

  • Share Price
  • $2.55
  • (As of Friday Closing)

Cognition Therapeutics General Information

Description

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Contact Information

Website
www.cogrx.com
Formerly Known As
Cognition Theraputics Inc
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 2500 Westchester Avenue
  • Purchase
  • New York, NY 10577
  • United States
+1 (412) 000-0000

Cognition Therapeutics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cognition Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.55 $2.60 $0.90 - $3.49 $102M 40.1M 165K -$0.92

Cognition Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 42,296 24,965 14,985 215,721
Revenue 0 0 0 0
EBITDA (28,490) (25,509) (21,134) (10,730)
Net Income (28,767) (25,788) (21,397) (11,716)
Total Assets 38,851 35,163 50,425 59,137
Total Debt 1,034 1,238 1,478 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cognition Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cognition Therapeutics‘s full profile, request access.

Request a free trial

Cognition Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Cognition Therapeutics‘s full profile, request access.

Request a free trial

Cognition Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, sm
Drug Discovery
New York, NY
25 As of 2022
00000
00000000 00000

000 00

r incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nos
0000 000000000
South San Francisco, CA
000 As of 0000
00000
00000 0000-00-00
000000000000 00000

0000 0

re et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ul
0000 000000000
San Diego, CA
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cognition Therapeutics Competitors (48)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NGM Biopharmaceuticals Private Equity-Backed South San Francisco, CA 000 00000 000000000000 00000
aTyr Pharma Formerly VC-backed San Diego, CA 00 00000 00000000 00000
Alector Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
Quince Therapeutics Formerly VC-backed South San Francisco, CA 00 00000 000000&0
Stealth BioTherapeutics Private Equity-Backed Needham, MA 00 00000 000000000000 00000
You’re viewing 5 of 48 competitors. Get the full list »

Cognition Therapeutics Patents

Cognition Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3212092-A1 Compositions and methods for treating neurologic diseases Pending 19-Mar-2021 0000000000
AU-2022239497-A1 Compositions and methods for treating neurologic diseases Pending 19-Mar-2021 0000000000
EP-4308565-A1 Compositions and methods for treating neurologic diseases Pending 19-Mar-2021 0000000000
AU-2021396380-A1 Compositions for treating dry age-related macular degeneration (amd) Pending 11-Dec-2020 0000000000
CA-3200346-A1 Compositions for treating dry age-related macular degeneration (amd) Pending 11-Dec-2020 A61K31/453
To view Cognition Therapeutics’s complete patent history, request access »

Cognition Therapeutics Executive Team (13)

Name Title Board Seat Contact Info
Lisa Ricciardi Chief Executive Officer & Board Member
Anthony Caggiano MD Chief Medical Officer & Executive
John Doyle Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
You’re viewing 3 of 13 executive team members. Get the full list »

Cognition Therapeutics Board Members (13)

Name Representing Role Since
Aaron Fletcher Ph.D Bios Partners Board Member 000 0000
Brett Monia Ph.D Self Board Member 000 0000
Jack Khattar Self Chairman & Board Member 000 0000
Lisa Ricciardi Cognition Therapeutics Chief Executive Officer & Board Member 000 0000
Peggy Wallace Golden Seeds Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Cognition Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cognition Therapeutics FAQs

  • When was Cognition Therapeutics founded?

    Cognition Therapeutics was founded in 2007.

  • Who is the founder of Cognition Therapeutics?

    Gilbert Rishton Ph.D is the founder of Cognition Therapeutics.

  • Who is the CEO of Cognition Therapeutics?

    Lisa Ricciardi is the CEO of Cognition Therapeutics.

  • Where is Cognition Therapeutics headquartered?

    Cognition Therapeutics is headquartered in New York, NY.

  • What is the size of Cognition Therapeutics?

    Cognition Therapeutics has 25 total employees.

  • What industry is Cognition Therapeutics in?

    Cognition Therapeutics’s primary industry is Drug Discovery.

  • Is Cognition Therapeutics a private or public company?

    Cognition Therapeutics is a Public company.

  • What is Cognition Therapeutics’s stock symbol?

    The ticker symbol for Cognition Therapeutics is CGTX.

  • What is the current stock price of Cognition Therapeutics?

    As of 24-May-2024 the stock price of Cognition Therapeutics is $2.55.

  • What is the current market cap of Cognition Therapeutics?

    The current market capitalization of Cognition Therapeutics is $102M.

  • Who are Cognition Therapeutics’s competitors?

    NGM Biopharmaceuticals, aTyr Pharma, Alector, Quince Therapeutics, and Stealth BioTherapeutics are some of the 48 competitors of Cognition Therapeutics.

  • What is Cognition Therapeutics’s annual earnings per share (EPS)?

    Cognition Therapeutics’s EPS for 12 months was -$0.92.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »